Kazia Therapeutics Ltd (KZIA): Utang agregat perusahaan

The Kazia Therapeutics (KZIA) price chart reflects debt dynamics, which currently stand at 0.00. The Australian business specializes in treating brain tumors, anticipating success for paxalisib in glioblastoma and the expansion of pediatric trials. However, trade conflicts and regulatory oversight hinder exports, while the R&D stage of small molecules prevents cost reduction as the company scales.

KZIA Utang perusahaan Kazia Therapeutics Ltd (04.07.2022 - 31.10.2026)

Rincian metrik lan analitis perusahaan Kazia Therapeutics (KZIA)

- kuotasi saiki lan rata-rata prakiraan nilai:

Rega bursa kaziatherapeutics.com|KZIA - Bagan rega target

- data kapitalisasi bursa:

Kapitalisasi pasar Kazia|KZIA - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Aset Bersih saben Saham Kazia Therapeutics|KZIA - Nilai Buku Perusahaan|Nilai Pasar marang Nilai Buku kaziatherapeutics.com|KZIA - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

- data bathi lan kelipatan valuasi:

KZIA - Bathi resik

Ringkesan analitik perusahaan:Kazia Therapeutics Ltd, KZIA

Low leverage enhances the fundamental stability of the issuer, minimizing default risks when assessing debt load through multiples. By analyzing the total debt volume, an investor sees the aggregate of all external obligations that Kazia Therapeutics (KZIA) utilizes to finance the development of Paxalisib and the integration of the drug into glioblastoma therapy protocols, which determines the balance between financial autonomy and the pace of ecosystem development.

Pesaing Kazia Therapeutics

INCY - Utang kumulatif perusahaan|Utang perusahaan HUTCHMED (China) Limited HCM|NUVB: Utang agregat perusahaan|Day One Biopharmaceuticals - Gunggung utang perusahaan|Utang kumulatif perusahaan Monopar Therapeutics Inc|Inhibrx Biosciences Inc (INBX) - Utang perusahaan|I-Mab Biopharma - Kewajiban utang agregat|FENC (Fennec Pharmaceuticals) - Gunggung utang perusahaan|Gunggung utang perusahaan Heron Therapeutics Inc|Utang perusahaan Nuvectis Pharma (NVCT)|Utang perusahaan CHRS (Coherus Biosciences)|Corbus Pharma - Gunggung utang perusahaan|Kewajiban utang agregat CRDF|BYSI - Utang perusahaan|Utang kumulatif perusahaan BioAtla, Inc.|Lixte Biotechnology Holdings, Inc. (LIXT) - Utang perusahaan|Utang agregat perusahaan CTXR|CLRB (Cellectar) - Gunggung utang perusahaan|Gunggung utang perusahaan BioLineRx Corporation (BLRX)|Utang perusahaan Can-Fite BioPharma (CANF)|APRE - Utang kumulatif perusahaan|Utang perusahaan Silexion Therapeutics SLXN|NuCana PLC - Utang perusahaan|CMRX - Utang perusahaan|Utang kumulatif perusahaan Cyclacel, Inc.|GTHX: Gunggung utang perusahaan|Tanggungan utang total perusahaan kronosbio.com KRON|Gunggung utang perusahaan KTRA|Utang kumulatif perusahaan Oncternal Therapeutics Inc ONCT|Gunggung utang perusahaan PRTG (Portage)